A Phase 2, Open-Label Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-Line Therapy in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer.

Trial Profile

A Phase 2, Open-Label Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-Line Therapy in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2015

At a glance

  • Drugs Ramucirumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 29 Sep 2012 Final results were presented at the Annual Congress of the European Society for Medical Oncology).
    • 22 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Oct 2011 Planned end date changed from 1 Sep 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top